ARVN
Arvinas, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +10.0% ·
share flow +9.6% ·
net new positions +9.1%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 78.53K | $605,140 | n/a | n/a |
| Q2 2026 | 82 | -2 | 34.83M | $289.66M | +6 | −8 |
| Q1 2026 | 87 | +4 | 31.95M | $338.79M | +7 | −3 |
| Q4 2025 | 83 | +1 | 38.40M | $455.50M | +2 | −1 |
| Q3 2025 | 15 | 0 | 28.59M | $243.63M | n/a | −1 |
| Q2 2025 | 13 | -1 | 30.77M | $226.45M | +1 | −2 |
| Q1 2025 | 11 | +1 | 13.86M | $97.33M | +1 | n/a |
| Q4 2024 | 10 | -1 | 12.65M | $242.44M | n/a | −1 |
| Q3 2024 | 10 | 0 | 10.38M | $255.76M | n/a | n/a |
| Q2 2024 | 10 | n/a | 10.17M | $270.82M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Citadel Advisors ✦ | 3.88M | +26.1% | $27.21M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 2 | T. Rowe Price ✦ | 3.83M | -6.8% | $26.85M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 3 | State Street Global Advisors ✦ (passive) | 1.90M | +15.8% | $13.31M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 1.54M | +1.7% | $10.79M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 5 | Millennium Management ✦ | 1.31M | +316.2% | $9.20M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Norges Bank ✦ (passive) | 1.01M | -19.0% | $7.08M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 7 | Renaissance Technologies ✦ | 132.30K | +92.0% | $928,746 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | Two Sigma Investments ✦ | 128.25K | -67.7% | $900,294 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 103.58K | New | $727,103 | 0.0% | New | 1 | SEC ↗ ×5 |
| 10 | Wellington Management ✦ | 27.73K | -6.7% | $194,680 | 0.0% | ▼ Trim | 4 | SEC ↗ ×4 |
| 11 | Marshall Wace ✦ | 20.49K | -92.4% | $143,833 | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| AQR Capital Management | $727,103 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 205 holders, 53.97M shares, $548.70M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.